NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through collaboration agreements. Key programs include elagolix (endometriosis) partnered with Abbott and GPR119 agonists (Type II diabetes) partnered with Boehringer Ingelheim.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Total revenues increased from $0.8 million in Q1 2010 to $12.5 million in Q1 2011. This was driven by the recognition of amortized upfront license fees and sponsored research revenue from new collaboration agreements with Abbott and Boehringer Ingelheim signed in June 2010.
• Profitability Turnaround: The company reported a net income of $2.9 million in Q1 2011, compared to a net loss of $8.6 million in Q1 2010. This shift was primarily due to the significant increase in collaboration revenue.
• Cash Position: Cash and cash equivalents decreased by approximately $30 million during the quarter, largely due to net cash used in operating activities ($8.6 million) and investing activities ($21.1 million), the latter driven by net purchases of investments.
• Operating Expenses: Total operating expenses decreased slightly by $0.3 million year-over-year, primarily due to reduced external development costs for the elagolix program, partially offset by increased personnel costs.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing capital resources ($121.6 million in cash and investments as of March 31, 2011), combined with interest income and future collaboration payments, will satisfy funding requirements for at least the next 12 months.
• Future Funding Needs: The company expects to incur operating cash flow losses for the foreseeable future and will require additional funding to continue R&D, clinical trials, and regulatory filings. It has a shelf registration statement for up to $125 million and a Committed Equity Financing Facility (CEFF) for up to $75 million.
• Key Risks:
  • Clinical Trial Failure: Product candidates may fail to demonstrate safety or efficacy, delaying or preventing regulatory approval.
  • Collaboration Dependence: The company relies heavily on Abbott and Boehringer Ingelheim for funding and commercialization; termination of these agreements would severely impact operations.
  • Indiplon Uncertainty: Significant uncertainty remains regarding the future development of the insomnia candidate indiplon following an FDA approvable letter in 2007 that required additional studies.
  • Profitability: While profitable for the quarter, the company has an accumulated deficit of $759.4 million and does not expect to be operating cash flow positive in 2011.

Investor Verification Checklist

• Collaboration Revenue Sustainability: Verify the amortization schedule for the Abbott and Boehringer Ingelheim upfront fees to understand the duration of the current revenue stream.
• Cash Burn Rate: Monitor the rate of cash consumption in operating activities versus the $121.6 million cash/investment balance to assess runway.
• Elagolix Development: Track progress of the lead candidate elagolix in Phase III trials, as this is the primary driver for future commercial milestones.
• Indiplon Status: Confirm if the company has made a decision on resubmitting the NDA for indiplon given the FDA's 2007 requirements.
• Equity Dilution: Review the terms of the CEFF with Kingsbridge Capital and the shelf registration statement for potential dilution impacts if additional capital is raised.